Inhibition of NK-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 23, Issue 3, 2005, Pages 323-330

  Okamoto, Hiroshi ^a   Iwamoto, Takuji ^a   Kotake, Shigeru ^a   Momohara, Shigeki ^a   Yamanaka, Hisashi ^a   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

NF B; Peroxisome proliferator activated receptor ; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CYTOKINE; FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN J2; ROSIGLITAZONE; STEROID; ANTILIPEMIC AGENT; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FIBROBLAST; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT OUTCOME; ANIMAL; ARTHRITIS; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; LEWIS RAT; METABOLISM; PATHOLOGY; SYNOVIUM;

ANIMALS; ANTILIPEMIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLASTS; HUMANS; LIGANDS; NF-KAPPA B; OSTEOCLASTS; PPAR ALPHA; PPAR GAMMA; PROCETOFEN; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 20444440328     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. FELDMANN M, BRENNAN FM, MAINI RN: Rheumatoid arthritis. Cell 1996; 85: 307-10.
2. HOPKINS SJ, MEAGER A: Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin. Exp Immunol 1988; 73: 88-92.
3. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
4. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
5. CAMPION GV, LEBSACK ME, LOOKA-BAUGH J, GORDON G, CATALANO M: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1092-101.
6. UDAGAWA N, TAKAHASHI N, AKATSU T et al.: Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990; 87: 7260-4.
7. REDDY SV, ROODMAN GD: Control of osteoclast differentiation. Crit Rev Eukaryotic Gene Expression 1998; 8: 1-17.
8. EGUCHI J, KOSHINO T, TAKAGI T, HAYASHI T, SAITO T: NF-kappa B and I-kappa B overexpression in articular chondrocytes with progression of type II collagen-induced arthritis in DBA/1 mouse knees. Clin Exp Rheumatol 2002; 20: 647-52.
9. MEYER-BAHLBURG A, GREIL S, KRUSE N, MARIENFELD R, SERFLING E, HUPPERTZ HI: Yersinia enterocolitica leads to transient induction of TNF-alpha and activates NF-kappaB in synovial fibroblasts. Clin Exp Rheumatol 2004; 22: 278-84.
10. FRANZOSO G, CARLSON L, XING L et al.: Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997; 11: 3482-96.
11. IOTSOVA V, CAAMANO J, LOY J et al.: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3, 1285-9.
12. MANGELSDORF DJ, THUMMEL C, BEATO M et al.: The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
13. RICOTE M, LI AC, WILSON TM, KELLY CJ, GLASS CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
14. JIANG C, TING AT, SEED B: PPAR-γ agonists inhibit pro-duction of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
15. StTAELS B, KOENIG W, HABIB A et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-793.
16. DELERIVE P, GERVOIS P, FRUCHART JC, STAELS B: Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000; 275: 36703-7.
17. TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation of adipogenesis in fibroblasts by PPAPg2, a lipid-activated transcription factor. Cell 1994; 79: 1147-56.
18. SPIEGELMAN BM, FLIER JS: Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
19. SERHAN CN: Inflammation. Signalling the fat controller. Nature 1996; 384: 23-4.
20. BRAISSANT O, FOUFELLE F, SCOTTO C, DAUCA M, WAHLI W: Differential expression of peroxisome proliferator activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinol 1996; 137: 354-66.
21. GREENE ME, BLUMBERG B, MCBRIDE OW et al.: Isolation of the human peroxisome proliferator-activated receptor γcDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4: 281-99.
22. CLARK RB, BISHOP-BAILEY D, ESTRADA-HERNANDEZ T, HLA T, PUDDINGTON L, PADULA SJ: The nuclear receptor PPAγ and immunoregulation: PPAγ mediates inhibition of helper T cell responses. J Immunol 2000; 164:1364-71.
23. SU CG, WEN X, BAILEY ST et al.: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104: 383-9.
24. WAYMA NS, HATTORI Y, McDONALD MC et al.: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002; 16: 1027-40.
25. YUE TL, CHEN J, BAO W et al.: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-94.
26. DIAB A, DENG C, SMITH JD et al.: Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 2508-15.
27. KAWAHITO Y, KONDO M, TSUBOUCHI Y et al.: 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000; 106: 189-97.
28. WANG C, FU M, D'AMICO M et al.: Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 2001; 21: 3057-70.
29. STRAUS DS, PASCUAL G, LI M et al.: 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000; 97: 4844-9.
30. ROSSI A, KAPAHI P, NATOLI G et al.: Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403: 103-8.
31. SAKURADA S, KATO T, OKAMOTO T: Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblastsand inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 1996; 8: 1483-
32. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1987; 31: 315-24.
33. YOSHIDA S, KATO T, SAKURADA S et al.: Inhibition of IL-6 and IL-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int Immunol 1999; 11: 151-8.
34. OKAMOTO H, CUJEC TP, OKAMOTO M, PETERLIN BM, BABA M, OKAMOTO T: Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 2000; 272: 402-408.
35. KOTAKE S, UDAGAWA N, HAKODA M et al.: Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001; 44: 1003-12.
36. TSURUMI K, KOKUBA S, OKADA K, YANAGIHARA M, FUJIMURA H: Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b,f] thiepin-2-y1]propionic acid. 4th communication: inhibitory effects on rat adjuvant arthritis. Arzneimittelforschung 1986; 36: 1810-7.
37. TAKAHASHI N, UDAGAWA N, SUDA T: A new members of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256: 449-55.
38. MBALAVIELE G, ABU-AMER Y, MENG A et al.: Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 2000; 275: 14388-93.
39. BROWN PJ, WINEGAR DA, PLUNKET KD et al.: A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. J Med Chem 1999; 42: 3785-8.
40. BEG AA, BALTIMORE D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996; 274: 782-4.
41. WANG CY, MAYO MW, BALDWIN JAS: TNF-and cancer therapy-induced apoptosis: protection by inhibition of NF-κB. Science 1996; 274: 784-8.
42. WU M, LEE H, BELLAS RE et al.: Inhibition of NF-κB/Rel induces apoptosis of murineB cells. EMBO J 1996; 15: 4682-90.
43. KALAJDZIC T, FAOUR WH, HE QW et al.: Nimesulfide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts. Arthritis Rheum 2002; 46: 494-506.
44. KOPP E, GHOSH S: Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994; 265: 956-9.
45. SCHEINMAN RI, COGSWELL PC, LOFQUIST AK, BALDWIN JAS: Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1994; 270: 283-6.
46. AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERG A, KARIN M: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-90.